Merck, Inc.
🇵🇭Philippines
Hemodynamic Effects of Rolofylline in the Treatment of Patients With Heart Failure (7418-503)
- First Posted Date
- 2008-08-07
- Last Posted Date
- 2015-10-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 60
- Registration Number
- NCT00729222
Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031)
Phase 3
Completed
- Conditions
- Osteoporosis
- Interventions
- First Posted Date
- 2008-08-07
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 214
- Registration Number
- NCT00729183
Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)
Phase 1
Completed
- Conditions
- Carcinoma, Non-small Cell Lung
- First Posted Date
- 2008-08-07
- Last Posted Date
- 2016-04-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 49
- Registration Number
- NCT00729742
A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)
Phase 4
Completed
- Conditions
- Ovarian Neoplasms
- Interventions
- First Posted Date
- 2008-08-05
- Last Posted Date
- 2017-06-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 58
- Registration Number
- NCT00727961
Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol and a Patient Assistance Program (Study P04671)
Completed
- Conditions
- Hepatitis C, ChronicHepatitis C
- Interventions
- Biological: PegIntron (peginterferon alfa-2b; SCH 54031)Drug: Rebetol (ribavirin; SCH 18908)Behavioral: Patient Assistance Program
- First Posted Date
- 2008-08-05
- Last Posted Date
- 2015-07-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 99
- Registration Number
- NCT00728494
Real-life Surveillance Study of Patients With Chronic Hepatitis C Treated With PegIntron Injector and Rebetol (Study P04538)(COMPLETED)
Completed
- Conditions
- Hepatitis CHepatitis C, Chronic
- Interventions
- Biological: PegIntron (peginterferon alfa-2b; SCH 54031) injectorDrug: Rebetol (ribavirin; SCH 18908)
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2302
- Registration Number
- NCT00727311
Post-marketing Surveillance of Children With Chronic Hepatitis C Treated With Intron A (Vial or Pen) and Rebetol (Study P04397)(TERMINATED)
Terminated
- Conditions
- Hepatitis CHepatitis C, Chronic
- Interventions
- Biological: IntronA (interferon alfa-2b; SCH 30500)Drug: Rebetol (ribavirin; SCH 18908)
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2015-04-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 3
- Registration Number
- NCT00727077
Post-marketing Surveillance Study of Ex-intravenous Drug Abusers With Chronic Hepatitis C Treated With PegIntron Plus Rebetol (P04408/MK-4031-261)
Completed
- Conditions
- Hepatitis C, ChronicSubstance Abuse, Intravenous
- Interventions
- Biological: PegIntron (pegylated interferon alfa-2b; SCH 54031)Drug: Rebetol (ribavirin; SCH 18908)
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 246
- Registration Number
- NCT00726557
Post-marketing Surveillance Study of Invasive Mycosis With Posaconazole (Study P04641)
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 214
- Registration Number
- NCT00726609
Diagnostic Criteria in the Diagnosis of Spinal Spondyloarthropathies in Patients With Chronic Low Back Pain (Study P05320)(COMPLETED)
Completed
- Conditions
- Spinal SpondyloarthropathiesAxial Spondyloarthritis
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1090
- Registration Number
- NCT00726765
© Copyright 2025. All Rights Reserved by MedPath